Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00835978 · ClinicalTrials.gov registry record · Phase 2
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 213
- Enrollment target
NCT00835978 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 213 participants.
The verdict
NCT00835978, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 213 participants
- Enrollment target
Study Summary
Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.
Interventions
- DRUG axitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2009-08 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00835978
The ClinicalTrials.gov registry entry for NCT00835978 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 213 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which axitinib is the first listed.
NCT00835978 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00835978 about?
NCT00835978 is a clinical study titled "Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer". Axitinib dose titration (giving a higher dose of the drug above its standard starting dose) among certain patients may improve the response to treatment.
What is the current status of trial NCT00835978?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 213 participants. The study started on 2009-08. Estimated completion is 2016-02.
What interventions are being tested in trial NCT00835978?
The interventions under investigation include: axitinib (DRUG).
Who is sponsoring clinical trial NCT00835978?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.